South Korean industry grapples with new rebate controls
This article was originally published in Scrip
Pharmaceutical companies in South Korea are having to work out how to comply with tougher controls on the provision of rebates and other promotional activities, which if contravened can now lead to substantial price cuts for individual drugs.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.